ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
ConditionHepatitis C
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKirby Institute
About this trial
The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for subsequent establishment of HCV screening and treatment programs in drug treatment clinics and NSPs across NSW and nationally.
Eligibility criteria
Qualifiers
Participant has voluntarily signed the informed consent form;
18 years of age or older;
History of injecting drug use*;
Recent injecting drug use (previous six months) or currently receiving OST*.
Disqualifiers
Nil
Trial design
Treatments tested in this trial
- Campaign days
Treatment groups
6,000 Participants
are divided into 1 treatment groupLocations
32Canberra Alliance for Harm Minimisation & Advocacy (CAHMA)2617, CanberraAustralian Capital Territory, Australia
Blacktown Methadone Management Clinic2148, BlacktownNew South Wales, Australia
NSLHD Brookvale Community Health Centre2100, BrookvaleNew South Wales, Australia
Campbelltown Drug Health Services2560, CampbelltownNew South Wales, Australia
Sponsors and collaborators
Kirby Institute
Lead sponsor
National Health and Medical Research Council, Australia
Collaborator
Source ClinicalTrials.gov